抗糖尿病药物对心房颤动风险的影响：来自临床证据和转化研究的机制见解。
Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
出版信息
Cell Mol Life Sci. 2021 Feb;78(3):923-934. doi: 10.1007/s00018-020-03648-y. Epub 2020 Sep 23.
Abstract
Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF), which is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Advanced glycation end product and its receptor activation, cardiac energy dysmetabolism, structural and electrical remodeling, and autonomic dysfunction are implicated in AF pathophysiology in diabetic hearts. Antidiabetic drugs have been demonstrated to possess therapeutic potential for AF. However, clinical investigations of AF in patients with DM have been scant and inconclusive. This article provides a comprehensive review of research findings on the association between DM and AF and critically analyzes the effect of different pharmacological classes of antidiabetic drugs on AF.
摘要
糖尿病（DM）是心房颤动（AF）的独立危险因素，AF 是最常见的持续性心律失常，与大量发病率和死亡率相关。晚期糖基化终产物及其受体激活、心脏能量代谢障碍、结构和电重构以及自主神经功能障碍与糖尿病心脏中的 AF 病理生理学有关。抗糖尿病药物已被证明对 AF 具有治疗潜力。然而，对 DM 患者 AF 的临床研究很少且尚无定论。本文全面回顾了 DM 和 AF 之间关联的研究结果，并批判性分析了不同类别的抗糖尿病药物对 AF 的影响。
相似文献
1
Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.抗糖尿病药物对心房颤动风险的影响：来自临床证据和转化研究的机制见解。
Cell Mol Life Sci. 2021 Feb;78(3):923-934. doi: 10.1007/s00018-020-03648-y. Epub 2020 Sep 23.
2
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂治疗 2 型糖尿病患者新发心房颤动的风险：一项全国性队列研究。
Cardiovasc Diabetol. 2022 Jun 28;21(1):118. doi: 10.1186/s12933-022-01549-x.
3
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.新型抗糖尿病药物在肾移植受者糖尿病管理中的应用评价。
Ann Pharmacother. 2021 Apr;55(4):496-508. doi: 10.1177/1060028020951955. Epub 2020 Aug 14.
4
Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.在真实世界应用中，二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂与骨折风险：观察性研究的系统评价和荟萃分析。
Osteoporos Int. 2019 Oct;30(10):1923-1940. doi: 10.1007/s00198-019-04968-x. Epub 2019 May 27.
5
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.二甲双胍治疗的 2 型糖尿病中伴有中度心血管风险患者的附加治疗：一项全国性研究。
Cardiovasc Diabetol. 2020 Jul 6;19(1):107. doi: 10.1186/s12933-020-01078-5.
6
Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.比较 2 型糖尿病患者使用降血糖药物相关的糖尿病视网膜病变事件：一项网络荟萃分析。
Diabetes Obes Metab. 2018 May;20(5):1262-1279. doi: 10.1111/dom.13232. Epub 2018 Feb 23.
7
Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.胰高血糖素样肽-1 受体激动剂与二肽基肽酶-4 抑制剂用于 2 型糖尿病合并晚期慢性肾脏病患者的死亡率相关。
JAMA Netw Open. 2022 Mar 1;5(3):e221169. doi: 10.1001/jamanetworkopen.2022.1169.
8
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.抗糖尿病药物与心房颤动/扑动风险：基于 SGLT2 抑制剂和 GLP-1 受体激动剂差异的比较性批判性分析。
Diabetes Metab. 2022 Nov;48(6):101390. doi: 10.1016/j.diabet.2022.101390. Epub 2022 Sep 25.
9
Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.基于深度学习神经网络的机器学习对 2 型糖尿病使用钠-葡萄糖共转运蛋白 2 抑制剂、二肽基肽酶-4 抑制剂或胰高血糖素样肽-1 受体激动剂的心肌梗死的比例风险分析。
Curr Med Res Opin. 2020 Mar;36(3):403-409. doi: 10.1080/03007995.2019.1706043. Epub 2020 Jan 6.
10
[Novel antidiabetic drugs and cardiovascular complications].[新型抗糖尿病药物与心血管并发症]
Ugeskr Laeger. 2018 Feb 5;180(6).
引用本文的文献
1
Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats.多组学揭示芪珀生脉颗粒降低老龄大鼠房颤易感性的机制。
Chin Med. 2025 Sep 3;20(1):118. doi: 10.1186/s13020-025-01154-6.
2
Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies.糖尿病中的心房颤动：发病机制与靶向性节律控制策略
Curr Issues Mol Biol. 2025 Jul 17;47(7):559. doi: 10.3390/cimb47070559.
3
Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling.钠-葡萄糖协同转运蛋白2抑制剂在心房重构中分子机制的最新研究进展
Curr Issues Mol Biol. 2024 Aug 31;46(9):9607-9623. doi: 10.3390/cimb46090571.
4
Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂和噻唑烷二酮类药物对2型糖尿病患者新发心房颤动风险的影响。
Rev Cardiovasc Med. 2022 Sep 9;23(9):303. doi: 10.31083/j.rcm2309303. eCollection 2022 Sep.
5
Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights.曲格列汀治疗 2 型糖尿病的临床疗效及安全性评价
Vasc Health Risk Manag. 2024 Jun 21;20:255-288. doi: 10.2147/VHRM.S391808. eCollection 2024.
6
Glucagon-like Peptide-1 Receptor Activation Reduces Pulmonary Vein Arrhythmogenesis and Regulates Calcium Homeostasis.胰高血糖素样肽-1 受体激活可减少肺静脉心律失常发生并调节钙稳态。
Int J Mol Sci. 2023 Aug 23;24(17):13100. doi: 10.3390/ijms241713100.
7
Atrial fibrillation and coronary artery disease: An integrative review focusing on therapeutic implications of this relationship.心房颤动与冠状动脉疾病：一项聚焦于这种关系治疗意义的综合综述。
World J Cardiol. 2023 May 26;15(5):229-243. doi: 10.4330/wjc.v15.i5.229.
8
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.用胰高血糖素样肽-1 受体激动剂预防中风：潜在机制的综合综述。
Cardiovasc Diabetol. 2022 Nov 15;21(1):242. doi: 10.1186/s12933-022-01686-3.
9
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂与老年 2 型糖尿病患者心房颤动事件的相关性。
JAMA Netw Open. 2022 Oct 3;5(10):e2235995. doi: 10.1001/jamanetworkopen.2022.35995.
10
Association between first-line monotherapy with metformin and the risk of atrial fibrillation (AMRAF) in patients with type 2 diabetes.二甲双胍作为一线单药治疗与 2 型糖尿病患者心房颤动（AMRAF）风险的相关性。
J Diabetes Complications. 2022 Nov;36(11):108315. doi: 10.1016/j.jdiacomp.2022.108315. Epub 2022 Sep 24.
本文引用的文献
1
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.达格列净对 2 型糖尿病患者心房颤动的影响：来自 DECLARE-TIMI 58 试验的见解。
Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27.
2
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
3
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2019 年更新：2018 年版《2 型糖尿病患者高血糖管理：美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）共识报告》。
Diabetologia. 2020 Feb;63(2):221-228. doi: 10.1007/s00125-019-05039-w.
4
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.恩格列净，一种钠-葡萄糖协同转运蛋白 2 抑制剂，可减轻高糖高脂饮食/链脲佐菌素诱导的糖尿病大鼠的心房重构并改善线粒体功能。
Cardiovasc Diabetol. 2019 Nov 28;18(1):165. doi: 10.1186/s12933-019-0964-4.
5
Mechanism of electrical remodeling of atrial myocytes and its influence on susceptibility to atrial fibrillation in diabetic rats.心房肌细胞电重构的机制及其对糖尿病大鼠心房颤动易感性的影响。
Life Sci. 2019 Dec 15;239:116903. doi: 10.1016/j.lfs.2019.116903. Epub 2019 Oct 19.
6
Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week.心房颤动与糖尿病：美国心脏病学会评论专题之周更
J Am Coll Cardiol. 2019 Aug 27;74(8):1107-1115. doi: 10.1016/j.jacc.2019.07.020.
7
Therapeutic potential of vitamin D in AGE/RAGE-related cardiovascular diseases.维生素 D 在 AGE/RAGE 相关心血管疾病中的治疗潜力。
Cell Mol Life Sci. 2019 Oct;76(20):4103-4115. doi: 10.1007/s00018-019-03204-3. Epub 2019 Jun 27.
8
Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway.二甲双胍通过 AMPK/PPAR-α/VLCAD 通路调节犬心房颤动模型中的脂质代谢。
Lipids Health Dis. 2019 May 10;18(1):109. doi: 10.1186/s12944-019-1059-7.
9
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.恩格列净通过增强心肌能量代谢改善非糖尿病心力衰竭的不良左心室重构。
J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056.
10
Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.恩格列净可减轻链脲佐菌素诱导的糖尿病大鼠心肌钠钙失调并逆转心脏重构。
Int J Mol Sci. 2019 Apr 4;20(7):1680. doi: 10.3390/ijms20071680.
Zotero 插件